Screener
West Pharmaceutical Services WST Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| (in millions, except per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Other current liabilities | 171.1 | 175.3 |
| Total current liabilities | 640.5 | 654.9 |
| Long-term debt | 202.9 | 202.8 |
| Deferred income taxes | 22.4 | 23.0 |
| Pension and other postretirement benefits | 28.3 | 29.0 |
| Operating lease liabilities | 88.3 | 95.6 |
| Deferred compensation benefits | 13.9 | 13.5 |
| Other long-term liabilities | 89.9 | 75.2 |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's deferred tax assets?
- West Pharmaceutical Services (WST) reported deferred tax assets of $22.4M in Q2 2026.
- How has West Pharmaceutical Services's deferred tax assets changed year-over-year?
- West Pharmaceutical Services's deferred tax assets decreased by 2.6% year-over-year, from $23M to $22.4M.
- What is the long-term trend for West Pharmaceutical Services's deferred tax assets?
- Over 5 years (2020 to 2025), West Pharmaceutical Services's deferred tax assets has grown at a 17.2% compound annual growth rate (CAGR), from $10.4M to $23M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about West Pharmaceutical Services's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude